비스테로이드소염제로 인한 궤양 합병증 예방을 위한 비스테로이드소염제 사용 현황 및 적절성 평가
Evaluation of NSAID Usage and Appropriateness for Prevention of NSAID-Related Ulcer Complications
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Nonsteroidal antiinflammatory drugs (NSAIDs) are used in the treatment of extensive diseases related to various symptoms;inflammation, pain and fever. NSAIDs work by blocking prostaglandin synthesis, but adverse drug events (ADEs)have been increasing dramatically such as gastrointestinal bleeding, perforation and stenosis, a kind of serious ADEs. Therefore, NSAID-related ulcer complication guidelines have been announced containing various risk factors and symptoms. Thus, this study aims to evaluate of NSAID usage and appropriateness for prevention of NSAID-related ulcer complication based on American journal of gastroenterology (AJG) guideline 2009. Further, the study suggests Korean guideline for prevention of NSAID-related ulcer compared to AJG guideline. For this study, data was collected through electronic medical record (EMR) at Seoul national university of Bundang hospital. The primary end point was a composite of NSAID-related ulcer risk factor, types of NSAIDs, co-prescribed NSAID ulcer prevention drugs and NSAIDrelated ulcer after taking NSAID. The risk factors include over 65 years, high dose NSAID, previous ulcer history and taking drugs (e.g. aspirin, anticoagulant and steroid) causing ulcer. If a patient has 3 or 4 factors, that patient was classified high risk group. And if 1 or 2 factors that patient was classified moderate risk group. The patient who has no risk factor was in low risk group. I studied 8,120 patients who received NSAID from 1 January 2009 to 31 December 2009. High risk group was 16(0.2%), moderate risk group was 4,364(53.7%), and low risk group was 3,740(46.1%). The results show that high risk group should be prescribed COX-2 inhibitors with ulcer prevention drugs, and moderate or low risk group need traditional NSAIDs with ulcer prevention drugs. This may be different with 2009 AJG guideline because AJG guideline suggested taking COX-2 inhibitor alone in moderate group or taking traditional NSAID alone in low risk group could get higher ulcer complication. The results indicated that choosing preventive drug is important in case that how many risk factors the patients have. The proper drugs would be helpful for safe and effective NSAID usage in each patient group.
Abstract
Nonsteroidal antiinflammatory drugs (NSAIDs) are used in the treatment of extensive diseases related to various symptoms;inflammation, pain and fever. NSAIDs work by blocking prostaglandin synthesis, but adverse drug events (ADEs)have been increasing dramatically such as gastrointestinal bleeding, perforation and stenosis, a kind of serious ADEs. Therefore, NSAID-related ulcer complication guidelines have been announced containing various risk factors and symptoms. Thus, this study aims to evaluate of NSAID usage and appropriateness for prevention of NSAID-related ulcer complication based on American journal of gastroenterology (AJG) guideline 2009. Further, the study suggests Korean guideline for prevention of NSAID-related ulcer compared to AJG guideline. For this study, data was collected through electronic medical record (EMR) at Seoul national university of Bundang hospital. The primary end point was a composite of NSAID-related ulcer risk factor, types of NSAIDs, co-prescribed NSAID ulcer prevention drugs and NSAIDrelated ulcer after taking NSAID. The risk factors include over 65 years, high dose NSAID, previous ulcer history and taking drugs (e.g. aspirin, anticoagulant and steroid) causing ulcer. If a patient has 3 or 4 factors, that patient was classified high risk group. And if 1 or 2 factors that patient was classified moderate risk group. The patient who has no risk factor was in low risk group. I studied 8,120 patients who received NSAID from 1 January 2009 to 31 December 2009. High risk group was 16(0.2%), moderate risk group was 4,364(53.7%), and low risk group was 3,740(46.1%). The results show that high risk group should be prescribed COX-2 inhibitors with ulcer prevention drugs, and moderate or low risk group need traditional NSAIDs with ulcer prevention drugs. This may be different with 2009 AJG guideline because AJG guideline suggested taking COX-2 inhibitor alone in moderate group or taking traditional NSAID alone in low risk group could get higher ulcer complication. The results indicated that choosing preventive drug is important in case that how many risk factors the patients have. The proper drugs would be helpful for safe and effective NSAID usage in each patient group.
참고문헌 (26)
- 김정욱, "비스테로이드소염제 유발 위창자병증", 대한소화기학회지, 52(3), pp.134~141 (2008), 대한소화기학회
- Aalykke C, "Epidemiology of NSAID-related gastroduodenal mucosal injury", Best Pract Res Clin Gastroenterol, 15, pp.705~722 (2001)
- Wolfe MM, "Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs", N Engl J Med, 340, pp.1888~1899 (1999)
- Lanza FL, "Guidelines for prevention of NSAIDrelated ulcer complications", Am J Gastroenterol, 104(3), pp.728~738 (2009)
- Macro Lazzaroni, "Management of NSAID-Induced Gastrointestinal Toxicity", Drugs, 69(1), pp.51~69 (2009)
- Aalykke C, "Epidemiology of NSAID-related gastroduodenal mucosal injury", Best Pract Res Clin Gastroenterol, 15, pp.705~722 (2001)
- Wolfe MM, "Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs", N Engl J Med, 340, pp.1888~1899 (1999)
- Shorr RI, "Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease", Arch Intern Med, 153, pp.1665~1670 (1993)
- Chou R, "Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review no. 4" (2006), Agency for Healthcare Research and Quality
- Gabriel SE, "Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta analysis", Ann Intern Med, 115, pp.787~796 (1991)
- Silverstein FE, "Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebocontrolled trial", Ann Intern Med, 123, pp.241~249 (1995)
- Bijlsma JW, "Treatment of NSAID-induced gastrointestinal lesions with cimetidine: an international multicenter collaborative study", Aliment Pharmacol Ther, 2, pp.85~95 (1988)
- Van Groeneandael JHLM, "The effect of ranitidine on NSAID-related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis or osteoarthritis", Clin Rheumatol, 15, pp.450~456 (1996)
- Taha AS, "Famotidine for the prevention of gastric a duodenal ulcers caused by nonsteroidal antiinflammatory drugs", N Engl J Med, 334, pp.1435~1439 (1996)
- Singh G, "Epidemiology of NSAID induced GI complications", J Rheumatol, 26, pp.18~24 (1999)
- Yun HR, "Korean costeffectiveness analysis of NSAIDs, NSAIDs with cotreatments to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis", Korean J Med, 60, pp.574~588 (2001)
- Yeomans ND, "A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine vs. Omeprazole for NSAID associated Ulcer Treatment (ASTRONAUT) Study Group", N Engl J Med, 338, pp.719~726 (1998)
- Hawkey CJ, "Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole vs. Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group", N Engl J Med, 33, pp.727~734 (1998)
- Lanza FL, "A blinded endoscopic comparative study of misoprostol vs. sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration", Am J Gastroenterol, 83, pp.143~146 (1988)
- Agrawal NM, "Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. a randomized, controlled trial", Ann Intern Med, 115, pp.195~200 (1991)
- McCarthy DM, "Sucralfate", N Engl J Med, 325, pp.1017~1025 (1991)
- Garcia Rodriguez LA, "Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal antiinflammatory drugs", Epidemiology, 12, pp.570~576 (2001)
- Hernandez-Diaz S, "Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding", perforation: an overview of epidemiologic studies published in the 1990s, 2000, pp.160, 2093~2099
- de Abajo FJ, "Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric coated formulations", BMC Clin Pharmacol, 1, pp.1~ (2001)
- Rostom A, "Prevention of NSAIDinduced gastroduodenal ulcers", Cochrane Database Syst Rev, 4, pp.CD002296~ (2002)
- Leontiadis GI, "Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding", Health Technol Assess, 11, pp.1~164 (2007)